Cinclus Pharma Holding AB CINPHA
OMXSTO · Sweden · Health Technology
SEK 13.26+0.06 (+0.45%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Claret Capital Partners provides €30m financing to Carvolix to accelerate commercialization of medtech portfolio Carvolix is a listed French commercial- and clinical-stage medical technology companyDeveloping breakthrough AI-driven mini-robots and biomimetic implants to revolutionize interventional cardiology and the treatment of ischaemic stroke Lead technology, TAVIpilot, an FDA-cleared, easy-to-use, AI-driven intraoperative software for TAVI (Transcatheter Aortic Valve Implantation) procedure
Claret Capital Partners invests €28M in Cinclus Pharma Cinclus Pharma is a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases Claret Capital Partners providing growth funding of up to €28M to enable earlier start of final stage of Cinclus Pharma’s Phase III clinical programAlso contributes to funding remaining development and pre-launch activities of Cinclus lead asset, linaprazan glurate, toward market approval and commercialisatio
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.